PEPTIDE GUIDE

What Is SS-31 / Elamipretide?

Elamipretide is a synthetic four-amino-acid peptide designed to concentrate at the inner mitochondrial membrane. It was developed under the names SS-31, MTP-131 and Bendavia and is supplied as elamipretide hydrochloride in the US medicine Forzinity.

In September 2025, the US Food and Drug Administration granted Forzinity accelerated approval for Barth syndrome in adults and children weighing at least 30 kilograms. The approval was based on improvement in knee-extensor muscle strength, a surrogate endpoint judged reasonably likely to predict clinical benefit. Continued approval depends on confirmatory evidence.

This narrow approval is important. It does not establish elamipretide as a general mitochondrial enhancer, anti-ageing treatment, exercise aid or therapy for every mitochondrial disease. Several controlled programmes outside Barth syndrome have produced mixed or negative primary outcomes.

Research statusFDA accelerated approval for defined Barth syndrome use
Compound typeMitochondria-targeting tetrapeptide
Human evidenceControlled trials with mixed condition-specific results
ApprovalUS accelerated approval for Barth syndrome
Last reviewedSeptember 2026
THE SHORT ANSWER

Elamipretide is the tetrapeptide D-Arg-dimethylTyr-Lys-Phe-NH2. It associates with cardiolipin-rich inner mitochondrial membranes and is intended to support membrane structure and energy-producing function under stress. Forzinity received US accelerated approval in 2025 for Barth syndrome in patients weighing at least 30 kg. The evidential basis was unusual because Barth syndrome is exceptionally rare: controlled trial results were limited, and FDA relied on knee-muscle-strength improvement judged likely to predict clinical benefit. Daily injection-site reactions are common. Trials in primary mitochondrial myopathy, heart failure and other conditions cannot be summarised as uniformly positive.

What is the molecule?

Elamipretide contains four residues, including D-arginine and a modified tyrosine. D-amino acids have the opposite handedness from the L-amino acids normally built into human proteins. Their inclusion can change enzyme resistance and distribution. The C-terminal amide is also part of the defined structure.

It is aromatic and positively charged. Those features help it associate with the negatively charged phospholipid cardiolipin without relying on the large electrical gradient used by some other mitochondria-targeting compounds.

SS-31 and elamipretide refer to the same active peptide programme. Salt form, formulation and pharmaceutical quality still matter. Forzinity is a regulated finished medicine; an online vial labelled SS-31 is not automatically equivalent.

Why can such a small peptide reach mitochondrial membranes?

Elamipretide is not a conventional targeting peptide with a long sequence that is imported through mitochondrial protein machinery. Its alternating aromatic and positively charged residues give it physicochemical properties that favour association with mitochondrial membranes.

The interaction is described as reversible rather than permanent. Elamipretide is proposed to concentrate near cardiolipin and membrane protein complexes without requiring covalent attachment. That may help explain why effects can appear under conditions of mitochondrial stress while the peptide itself does not replace a defective respiratory-chain protein.

This mechanism also sets a limit on what should be claimed. Supporting membrane organisation cannot repair every pathogenic mitochondrial DNA or nuclear DNA variant. It does not restore the missing tafazzin enzyme in Barth syndrome, and it cannot reverse tissue already lost to fibrosis or longstanding disease.

What is cardiolipin and why does it matter?

Cardiolipin is a distinctive phospholipid concentrated in the inner mitochondrial membrane. It helps organise protein complexes involved in oxidative phosphorylation, the process that uses nutrients and oxygen to make adenosine triphosphate, or ATP.

Barth syndrome is caused by pathogenic variants in TAZ, a gene needed to remodel cardiolipin. Abnormal cardiolipin disrupts mitochondrial structure and function, affecting heart and skeletal muscle among other systems.

Elamipretide is described as associating with cardiolipin and helping stabilise membrane organisation. Laboratory studies report effects on electron transport, cristae structure and reactive-oxygen chemistry. A mechanistic effect does not guarantee a clinical effect, particularly when irreversible tissue injury or a different disease mechanism dominates.

Why is Barth syndrome a particularly relevant disease?

TAZ encodes tafazzin, an enzyme involved in remodelling cardiolipin. Pathogenic variants can produce abnormal cardiolipin composition, disturbed inner-membrane architecture and impaired mitochondrial energy metabolism. Clinical features can include cardiomyopathy, skeletal-muscle weakness, exercise intolerance, growth problems and episodes of neutropenia.

This creates a closer connection between elamipretide’s proposed membrane interaction and the disease defect than exists in a broad category such as “fatigue” or “ageing”. Even so, a mechanistic match is not proof. Barth syndrome affects several organ systems, varies between patients and is exceptionally rare, making conventional large outcome trials difficult.

The FDA indication is correspondingly narrow: improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kilograms. It should not be rewritten as approval for mitochondrial disease in general.

How was elamipretide developed?

The Szeto-Schiller peptide family was developed from studies of small aromatic-cationic peptides that entered mitochondria. Elamipretide advanced through models of ischaemia, muscle dysfunction and inherited mitochondrial disease.

PeriodDevelopment
2000sSS peptides characterised in mitochondrial and oxidative-stress models
2010sEarly clinical studies expanded into cardiac, renal and primary mitochondrial conditions
2017 to 2020MMPOWER and TAZPOWER programmes reported controlled human results
September 2025FDA granted Forzinity accelerated approval for Barth syndrome in patients at least 30 kg
Post-approvalConfirmatory evidence remains required to verify clinical benefit

What did the Barth syndrome trial show?

TAZPOWER began with a randomised, double-blind, placebo-controlled crossover period in 12 participants. Elamipretide did not significantly improve the primary six-minute walk or symptom outcome during the initial controlled comparison.

Participants then entered an open-label extension. Longer-term observations, natural-history comparisons and knee-extensor strength contributed to the eventual regulatory case. Open-label improvement is harder to interpret because everyone knows treatment is being received and there is no concurrent placebo group.

FDA used accelerated approval, accepting change in knee-extensor strength as reasonably likely to predict benefit such as easier standing or walking. This is not the same evidential position as a large trial showing fewer hospitalisations or longer survival. A confirmatory study must verify clinical benefit.

What happened in the controlled and open-label phases?

The controlled crossover enrolled 12 participants. Each treatment period lasted 12 weeks and was separated by a washout. Neither the six-minute walk test nor the Barth Syndrome Symptom Assessment primary endpoint showed a statistically significant treatment advantage during that blinded comparison.

Ten participants entered the open-label extension and eight reached 36 weeks. Relative to their earlier baseline, those eight had a reported mean 95.9-metre improvement in six-minute walk distance and a 56-newton improvement in knee-extensor strength. Symptoms and some secondary measures also moved favourably.

Those longer-term changes are encouraging but less secure than a blinded, concurrent comparison. Practice with the walking test, expectation, changes in health, regression to the mean and selective continuation can all influence an open-label result. With only eight participants at week 36, one person can materially affect the average.

Why did FDA use an intermediate clinical endpoint?

Accelerated approval can be based on a surrogate or intermediate endpoint judged reasonably likely to predict benefit in a serious condition with unmet need. In this case, FDA accepted knee-extensor muscle strength rather than waiting for a large trial demonstrating survival or hospitalization benefit.

Knee-extensor strength is clinically meaningful because it contributes to standing, climbing and walking, but it is not identical to those whole-person abilities. The confirmatory requirement exists to determine whether the measured strength gain translates into sustained clinical benefit.

What happened in primary mitochondrial myopathy?

MMPOWER evaluated short intravenous exposure in adults with genetically confirmed primary mitochondrial myopathy. It examined walking and fatigue-related outcomes. The programme produced dose and subgroup signals but did not establish broad efficacy across the heterogeneous disease group.

MMPOWER-2 used subcutaneous treatment in a crossover design. Later Phase III work also struggled to demonstrate clear primary-outcome benefit. “Mitochondrial disease” covers many genetic defects, tissues and stages; one membrane-targeting mechanism may not overcome every cause.

MMPOWER-2 enrolled 30 adults. The estimated treatment difference in six-minute walk distance was 19.8 metres, with a 95% confidence interval from -2.8 to 42.5 metres and a p value of 0.0833. That is an efficacy signal, not a statistically established effect.

MMPOWER-3 was the larger test. It randomized 218 participants to 24 weeks of daily subcutaneous elamipretide or placebo. The treatment difference was -3.2 metres on the six-minute walk test, and the fatigue endpoint also did not differ significantly. The publication classified this as Class I evidence that elamipretide did not improve those outcomes in the overall primary-mitochondrial-myopathy population studied.

Later genotype analyses can help generate future hypotheses, but a post hoc or subgroup signal does not reverse the negative primary result. It requires prospective confirmation in a population defined before randomization.

These results are not inconsistent with a Barth-specific approval. They show that benefit cannot be generalised from one mitochondrial disorder to another.

What did heart and kidney studies find?

Elamipretide has been examined in heart failure, acute myocardial infarction, kidney disease and renovascular disease. Some small mechanistic studies reported changes in mitochondrial or cardiac measures. Larger controlled studies did not consistently meet their primary clinical or imaging endpoints.

This is a common development pattern: a plausible mitochondrial mechanism and encouraging animal data do not ensure that a short human intervention reverses established organ disease. Individual trials should be read by condition, endpoint and route rather than pooled into a claim that SS-31 “repairs mitochondria”.

How is elamipretide manufactured?

As a tetrapeptide, elamipretide can be assembled by solid-phase peptide synthesis using protected amino-acid building blocks. The unusual D-arginine, dimethyltyrosine and terminal amide must be introduced and confirmed correctly.

Purification can use preparative chromatography. Identity testing can include mass spectrometry and chromatographic comparison, while chiral or sequence-sensitive methods help detect wrong stereochemistry. Testing must also cover related peptide impurities, residual solvents, counterions, content and potency.

The approved injection additionally requires validated sterility, endotoxin, particle, concentration, stability and container-closure controls. A high HPLC percentage alone does not establish these properties.

What distinguishes the approved medicine from an “SS-31” vial?

Forzinity has a defined active ingredient, salt form, concentration, excipients, container system and labelled storage conditions. Manufacturing batches must meet validated specifications, and changes are controlled within the regulated supply chain.

A credible analysis of an unregulated peptide would need to establish intact mass, sequence, the D-configuration of arginine, the dimethyltyrosine residue, C-terminal amidation, related impurities, content and counterion. Injectable quality additionally requires sterility, endotoxin and particulate testing. Chromatographic purity alone cannot show all of this.

Even a chemically correct copy would not acquire the approved product’s evidence automatically. Formulation, stability, concentration accuracy and supply-chain controls are parts of product equivalence, not optional details.

What are the adverse effects and warnings?

Injection-site reactions are the most prominent labelled adverse effect. Repeated daily subcutaneous administration means local pain, redness, swelling or other reactions can materially affect treatment burden.

The authorised label should be consulted for contraindications, precautions, paediatric information and handling. Evidence in Barth syndrome is based on a tiny population, so rare harms are difficult to estimate. Post-marketing surveillance and confirmatory study are especially important.

The medicine's US approval does not make non-prescribed products safe. Incorrect strength, contamination or aggregation can create risks absent from the authorised supply chain.

What is the regulatory position?

Forzinity is FDA approved under the accelerated-approval pathway for Barth syndrome in adults and children weighing at least 30 kg. Accelerated approval is real approval, but it is conditional on verification of clinical benefit. FDA can alter or withdraw approval if confirmatory evidence fails.

Approval is jurisdiction-specific. It should not be described as UK or EU authorisation without checking those regulators. It also does not cover anti-ageing, athletic performance or unrelated mitochondrial conditions.

How strong is the evidence overall?

QuestionBest available evidenceDefensible conclusion
Does elamipretide have an authorized use?FDA accelerated approval and prescribing informationYes, for improving muscle strength in the defined Barth syndrome population
Did the blinded Barth crossover meet its primary endpoints?Twelve-participant randomized crossover trialNo
Is there evidence of longer-term strength improvement in Barth syndrome?Very small open-label extension and regulatory analysisA signal supported accelerated approval; clinical benefit still requires confirmation
Does it treat primary mitochondrial myopathy broadly?218-participant Phase III trialNo benefit on the primary walking or fatigue endpoints in the overall population
Does it reverse ageing or improve healthy performance?No adequate controlled human trialsClaims are unsupported

There is enough evidence for a detailed account because elamipretide is now a regulated medicine with several controlled programmes. There is not enough evidence to turn its narrow approval into a general mitochondrial-health claim.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is SS-31 the same as elamipretide?

Yes. SS-31 is an earlier research name for elamipretide.

What is Forzinity?

It is the US-approved elamipretide hydrochloride product for a defined Barth syndrome population.

How many amino acids does it contain?

Four, including modified and D-form residues.

Is it FDA approved?

Yes, under accelerated approval for Barth syndrome in patients weighing at least 30 kg.

Does accelerated approval mean experimental?

It is legal FDA approval, but continued approval depends on confirmatory evidence of clinical benefit.

Does it cure Barth syndrome?

No. It does not correct the underlying TAZ gene variant.

Does it treat every mitochondrial disease?

No. Other controlled programmes have had mixed or negative primary results.

Does it reverse ageing?

No controlled human evidence establishes an anti-ageing treatment effect.

What is cardiolipin?

It is a phospholipid central to inner mitochondrial membrane organisation.

What is the most common tolerability issue?

Injection-site reactions are prominent with daily subcutaneous use.

Are online SS-31 products equivalent to Forzinity?

No. Product identity and pharmaceutical controls have to be established independently.

Are clinical amounts personal-use instructions?

No. This guide does not provide dosing or administration advice.

RESEARCH AND MEDICAL NOTICE

This guide is educational. It does not recommend elamipretide or provide personal treatment, dosing, preparation or sourcing advice.

Research reviewed through September 2026.